SCHEMBL30730618

SCHEMBL30730618

Cc1nonc1CC(=O)N1CCC(n2nnc(-c3ccc(Cl)cc3)n2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.54
ALDH1A1 P00352 2/20 0.42
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
POLB P06746 1/20 0.41
ENPP2 Q13822 1/20 0.41
HSD11B1 P28845 1/20 0.41
TSHR P16473 1/20 0.40
GFER P55789 1/20 0.40
RAB9A P51151 2/20 0.39
LMNA P02545 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730663 0.92 PKM (0.44) PKMALDH1A1DRD2DRD4DRD3
SCHEMBL30730585 0.90 LMNA (0.47) PKMALDH1A1DRD2DRD4DRD3
SCHEMBL32676970 0.90 RAB9A (0.50) PKMALDH1A1DRD2DRD4DRD3
SCHEMBL30730540 0.90 PKM (0.44) PKMALDH1A1DRD2DRD4DRD3
SCHEMBL30730596 0.88 ENPP2 (0.42) PKMALDH1A1ENPP2TSHRGFER
SCHEMBL30730693 0.83 PKM (0.45) PKMALDH1A1ENPP2GFERRAB9A
SCHEMBL30730615 0.83 GRM5 (0.43) PKMALDH1A1DRD2DRD4DRD3
SCHEMBL30730517 0.83 POLB (0.48) ALDH1A1DRD2DRD4DRD3POLB
SCHEMBL30730446 0.82 LMNA (0.57) PKMHSD11B1TSHRLMNAHTT
SCHEMBL30730647 0.81 RAB9A (0.46) PKMALDH1A1POLBTSHRGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 PKM 2873/4885ALDH1A1 2154/4885DRD2 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.